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ASBT

:   apical sodium‐dependent bile acid transporter

BA

:   bile acid

BSEP

:   bile salt export pump

CA

:   cancer antigen

CDCA

:   chenodeoxycholic acid

Chol

:   cholesterol

Col1α, collagen 1α; COX2

:   cyclooxygenase 2

eNOS

:   endothelial NO synthase

ET1

:   endothelin 1

FA

:   fatty acid

FFA

:   free fatty acid

FGF

:   fibroblast growth factor

FGFR

:   FGF receptor

FXR

:   farnesoid X receptor

HCC

:   hepatocellular carcinoma

HDL

:   high‐density lipoprotein

IFN

:   interferon

IGF1R

:   insulin‐like growth factor 1 receptor

IL

:   interleukin

iNOS

:   inducible NO synthase

KC

:   Kupffer cell

LDL

:   low‐density lipoprotein

LDLr

:   LDL receptor

Lp(a), lipoprotein a; LSEC

:   liver sinusoidal endothelial cell

MCP1

:   monocyte chemoattractant protein 1

MDR

:   multidrug resistance

MMP

:   matrix metalloproteinase

NAFLD

:   nonalcoholic fatty liver disease

NASH

:   nonalcoholic steatohepatitis

NFκB

:   nuclear factor kappa B

NO

:   nitric oxide

NTCP

:   sodium/taurocholate cotransporting polypeptide

PL

:   phospholipids

SR‐BI

:   scavenger receptor class B type 1

p‐STAT3

:   phosphorylated signal transducer and activator of transcription 3

TG

:   triglyceride

TGF

:   transforming growth factor

TIMP

:   tissue inhibitor of metalloproteinase

TJ

:   tight junction

TNF

:   tumor necrosis factor

VCAM

:   vascular cell adhesion molecule

VLDL

:   very low‐density lipoprotein

ZO‐1

:   zona occludens 1.
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